Stock MOREPENLAB MOREPEN LABORATORIES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Morepen Laboratories Limited NSE India S.E.

Equities

MOREPENLAB

INE083A01026

Pharmaceuticals

Market Closed - NSE India S.E.
Other stock markets
 07:43:49 2024-05-02 am EDT 		5-day change 1st Jan Change
50.3 INR +0.50% Intraday chart for Morepen Laboratories Limited -2.90% +3.60%
Mar. 30 Morepen Laboratories Limited Announces Resignation of Lalit Kumar Baregama, Chief Growth Officer CI
Mar. 01 Morepen Laboratories Limited Announces the Promotion of Amita Sharma to Chief Operating Officer -API CI

Valuation

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Capitalization 1 13,877 7,760 4,291 14,462 17,488 13,127
Enterprise Value (EV) 1 15,160 8,979 5,486 15,415 18,663 13,162
P/E ratio 46.9 x 27 x 12.8 x 15 x 18.7 x 33.4 x
Yield - - - - - -
Capitalization / Revenue 2.27 x 1.01 x 0.5 x 1.21 x 1.12 x 0.92 x
EV / Revenue 2.48 x 1.16 x 0.64 x 1.29 x 1.2 x 0.93 x
EV / EBITDA 23.2 x 14 x 8.19 x 12.5 x 13.9 x 19.2 x
EV / FCF 72.3 x -149 x -31.9 x -54.9 x -13 x -47.9 x
FCF Yield 1.38% -0.67% -3.13% -1.82% -7.71% -2.09%
Price to Book 6.14 x 3.07 x 1.51 x 3.4 x 3.02 x 1.74 x
Nbr of stocks (in thousands) 449,826 449,826 449,826 449,826 477,826 511,169
Reference price 2 30.85 17.25 9.540 32.15 36.60 25.68
Announcement Date 8/13/18 8/20/19 9/5/20 9/4/21 9/2/22 9/4/23
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 6,101 7,714 8,584 11,980 15,558 14,220
EBITDA 1 654.2 641.7 670.3 1,230 1,338 686.6
EBIT 1 340.1 304.7 369 981.7 1,180 560.8
Operating Margin 5.57% 3.95% 4.3% 8.19% 7.58% 3.94%
Earnings before Tax (EBT) 1 297.7 291.8 391.1 985.1 1,267 557.6
Net income 1 295.9 288.5 335.8 970.9 1,017 386.8
Net margin 4.85% 3.74% 3.91% 8.1% 6.54% 2.72%
EPS 2 0.6578 0.6400 0.7465 2.150 1.960 0.7700
Free Cash Flow 1 209.7 -60.09 -171.9 -280.6 -1,440 -275
FCF margin 3.44% -0.78% -2% -2.34% -9.25% -1.93%
FCF Conversion (EBITDA) 32.05% - - - - -
FCF Conversion (Net income) 70.86% - - - - -
Dividend per Share - - - - - -
Announcement Date 8/13/18 8/20/19 9/5/20 9/4/21 9/2/22 9/4/23
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 1,283 1,220 1,195 953 1,174 35
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 1.961 x 1.901 x 1.783 x 0.7749 x 0.8774 x 0.0509 x
Free Cash Flow 1 210 -60.1 -172 -281 -1,440 -275
ROE (net income / shareholders' equity) 14.1% 12.1% 12.5% 27.4% 20.3% 5.81%
ROA (Net income/ Total Assets) 3.78% 3.17% 3.61% 8.06% 7.65% 3.21%
Assets 1 7,824 9,097 9,308 12,039 13,292 12,031
Book Value Per Share 2 5.020 5.630 6.310 9.440 12.10 14.70
Cash Flow per Share 2 0.1300 0.2100 0.3000 0.9200 0.3300 0.4200
Capex 1 103 85.1 167 218 454 356
Capex / Sales 1.69% 1.1% 1.94% 1.82% 2.92% 2.5%
Announcement Date 8/13/18 8/20/19 9/5/20 9/4/21 9/2/22 9/4/23
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+29.68% 699B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+25.07% 571B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.35% 364B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.65% 326B
ABBVIE INC. Stock AbbVie Inc.
+3.77% 286B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.68% 236B
NOVARTIS AG Stock Novartis AG
+4.71% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-12.43% 194B
PFIZER, INC. Stock Pfizer, Inc.
-3.79% 154B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. MOREPENLAB Stock
  4. MOREPENLAB Stock
  5. Financials Morepen Laboratories Limited